Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK), G. J. Ossenkoppele*, D. A. Breems, Georg Stuessi, Y. van Norden, M. Bargetzi, B. J. Biemond, P. A von dem Borne, Y. Chalandon, J. Cloos, D. Deeren, M. Fehr, B. Gjertsen, C. Graux, G. Huls, J. J.W.M. Janssen, A. Jaspers, M. Jongen-Lavrencic, E. de Jongh, S. K. KleinM. Van der Klift, M. van Marwijk Kooy, J. Maertens, L. Michaux, M. W. M. van der Poel, A. van Rhenen, L. Tick, P. Valk, M. C. Vekemans, W. J.F.M. van der Velden, O. de Weerdt, T. Pabst, M. G. Manz, B. Löwenberg

*Corresponding author for this work

    Research output: Contribution to journalErratum

    Abstract

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

    Original languageEnglish
    Pages (from-to)2820
    Number of pages1
    JournalLeukemia
    Volume34
    Issue number10
    DOIs
    Publication statusPublished - 1-Oct-2020

    Fingerprint

    Dive into the research topics of 'Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)'. Together they form a unique fingerprint.

    Cite this